Autolus Therapeutics plc

The conference will begin shortly. To raise and lower your hand during Q&A, you can dial star 1-1.

Ladies and gentlemen, and welcome to the Altalus Therapeutics full year 2022 financial results conference call and fourth quarter operational progress. As a reminder, this conference is being recorded. I would now like to turn the conference over to your host, Julia Wilson, communications consultant. Please go ahead.

Thank you, Norma. Good morning or good afternoon, everyone, and thank you for joining us to take part in today's call on the full year 2022 financial results and operational highlights for the fourth quarter 2022. I'm Julia Wilson, a communications consultant for Autolis. With me today are Dr. Christian Eytin, our Chief Executive Officer, and Dr. Lucinda Crabtree, our Chief Financial Officer. Before we begin, I would like to remind you that during today's call, we will make statements related to our business that are forward-looking under federal securities laws and the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These may include, but are not limited to, statements regarding the status of clinical trials and development timelines for our product candidates. and our expectations regarding our cash runway. These statements are subject to a variety of risks and uncertainties that could cause actual results to differ materially from expectations and reflect our views only as of today. We assume no obligation to update any such forward-looking statements. For discussion of the material risks and uncertainties that could affect our actual results, please refer to the risks identified in today's press release and our SEC filings, both available on the investor section of our website. On slide three, you will see the agenda for today, which is as follows. Christian will provide an overview of our operational highlights for the fourth quarter of 2022. Lucinda will then discuss the company's full year financial results before Christian will conclude with upcoming milestones and any other concluding comments. Finally, we will, of course, welcome your questions. Over to you, Christian.